Overview
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 15, 2025 | Helmsley Charitable Trust Awards $500,000 to Genetic Alliance: Global Access to Genomic Testing for Underserved Children | Join iHope Genetic Health We are expanding rapidly... A diagnosis opens the door to treatment, connection, and hope—and Helmsley’s partnership helps us unlock those doors.” — Sharon F. Terry, CEODAMASCUS, MD, UNITED STATES, July 15, 2025 /E... |
| May 6, 2025 | The Rising Tide of Inflammatory Bowel Disease: A Global Perspective | Inflammatory Bowel Disease (IBD) is a silent storm brewing across the globe. This chronic condition, which includes Crohn's disease and ulcerative colitis, is not just a medical issue; it’s a societal challenge. A recent study led by The Ch... |
| May 6, 2025 | The AI Talent Exodus: A Wake-Up Call for America | America has long been the shining beacon of innovation. The land of opportunity, where dreams are forged into reality. But a storm brews on the horizon. The latest research reveals a troubling trend: the United States is losing its edge in ... |
| May 6, 2025 | Peas and Progress: A New Era in Sustainable Agriculture | In the world of agriculture, peas are stepping into the spotlight. An international research collaboration has unlocked a treasure trove of genetic information that could transform pea crops into sustainable powerhouses. This breakthrough i... |
| May 1, 2025 | A global study led by CUHK and the University of Calgary charts four-stage evolution of Inflammatory Bowel Disease | HONG KONG, May 1, 2025 /PRNewswire/ -- An international consortium led by The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and the University of Calgary in Canada has conducted a global epidemiological study on... |
| Sep 10, 2024 | Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation | Abvance is developing ABV100, a proprietary, clinically validated combination of insulin and glucagon with a goal of improving glycemic control while reducing hypoglycemia for people with diabetes who require rapid acting insulinABV100 has ... |
| Sep 10, 2024 | Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation | Abvance is developing ABV100, a proprietary, clinically validated combination of insulin and glucagon with a goal of improving glycemic control while reducing hypoglycemia for people with diabetes who require rapid acting insulin ABV100 has... |
| Aug 21, 2024 | The STAR Consortium Announces a Major Milestone in Crohn's Disease Intestinal Strictures Imaging | The consortium of researchers from Alimentiv Inc., Cleveland Clinic, and Mayo Clinic are supported by The Leona M. and Harry B. Helmsley Charitable Trust NEW YORK, Aug. 21, 2024 /PRNewswire/ -- In a recent innovation for Crohn's disease tre... |
| Oct 24, 2023 | Insulin is increasingly affordable in the U.S. What about the rest of the world? | In March, Eli Lilly, Novo Nordisk, and Sanofi — the world’s three largest insulin manufacturers — committed to reducing the U.S. list price of insulin, a drug that millions of people require to live. Following two decades of sharp increases... |
Reviews 0
FAQ about The Helmsley Charitable Trust
When was The Helmsley Charitable Trust founded?
The Helmsley Charitable Trust was founded in 1930.
What has the press written about The Helmsley Charitable Trust?
Parsers VC has collected 18 articles mentioning The Helmsley Charitable Trust, among them “Helmsley Charitable Trust Awards $500,000 to Genetic Alliance: Global Access to Genomic Testing for Underserved Children” (Jul 15, 2025) and “The Rising Tide of Inflammatory Bowel Disease: A Global Perspective” (May 6, 2025).
Is The Helmsley Charitable Trust still active?
Yes, The Helmsley Charitable Trust is active; its latest activity on Parsers VC dates from Aug 18, 2025.